Coloplast raises earnings expectations

Revenue was up 7% to DKK 5,346m in the first half of the financial year 2011/2012 and the EBIT margin was 27% against 24% during the same period last year.

Read the announcement: English Danish

"I’m very pleased. We continue to grow more than the market and have delivered a solid result which means we can raise our earnings expectations for this financial year," says CEO Lars Rasmussen.

The revenue growth expectations for the financial year 2011/2012 continue to be about 6% at constant exchange rates and about 8% in DKK based on current exchange rates. The EBIT margin is raised from about 27% to about 28% at constant exchange rates and from about 28% to around 29% in DKK based on current exchange rates.

 

Ready to invest in growth

Coloplast's Board of Directors today approved an updated strategy for the next 3-5 years which aims to accelerate growth.

"The combination of a strong portfolio of new products and a stronger, more professional sales force means that we now have the foundation to accelerate growth."

"Furthermore, we have over the past four years improved the company's profitability significantly which means that we are now ready to invest up to 1 billion Danish kroner in growth during the next five years while maintaining earnings in line with the best in the market, "says Lars Rasmussen.

The future investments should maintain and strengthen Coloplast's position as market leader in Europe, strengthening growth in the developed markets outside Europe (U.S., Canada, Japan and Australia) as well as providing greater expansion into new markets including China.

Coloplast today announced a new sales organisation, which supports the updated strategy. For more details go to H1 announcement.

Coloplast's long-term financial ambition is to outgrow the market while achieving earnings margins that are in line with the best performing med-tech companies.